Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors.
In the present study, the antitumor activity of some water-soluble ferricenium complexes [(C5H5)2Fe]+ X- (I, X- = [FeCl4]-; II, X- = 1/2[Cl3FeOFeCl3]2-; III, X- = [2,4,6-(NO2)3C6H2O]-; IV, X- = [CCl3COO]- 2CCl3COOH) was investigated against the solid, subcutanteously growing tumors sarcoma 180, B16 melanoma and colon 38 adenocarcinoma. Whereas, in the case of solid sarcoma 180, only marginal antitumor activity was observed for I-IV, the compounds effected growth inhibitions of solid B16 melanoma and colon 38 carcinoma by 35-60% and 50-73%, respectively, resulting in T/C ratios of 40-65% and 27-50%. In most tests, ferricenium trichloroacetate IV, followed by ferricenium mu-oxo-bis(trichloroferrate) II, were characterized by best antitumor properties against the tumor models investigated.
Köpf-Maier
P
P
Analytische Chemie der Technischen Universität, Berlin-West Germany.
Klapötke
T
T
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D003517:Cyclopentanes / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D007501:Iron / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000627:therapeutic use* / Q000633:toxicity; D012510:Sarcoma 180 / Q000188:drug therapy
D000970:Antineoplastic Agents; D003517:Cyclopentanes; D009942:Organometallic Compounds; D007501:Iron